Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • JASN Podcasts
    • Article Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Editorial Fellowship
    • Editorial Fellowship Team
    • Editorial Fellowship Application Process
  • More
    • About JASN
    • Advertising
    • Alerts
    • Feedback
    • Impact Factor
    • Reprints
    • Subscriptions
  • ASN Kidney News
  • Other
    • ASN Publications
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • ASN Publications
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • JASN Podcasts
    • Article Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Editorial Fellowship
    • Editorial Fellowship Team
    • Editorial Fellowship Application Process
  • More
    • About JASN
    • Advertising
    • Alerts
    • Feedback
    • Impact Factor
    • Reprints
    • Subscriptions
  • ASN Kidney News
  • Follow JASN on Twitter
  • Visit ASN on Facebook
  • Follow JASN on RSS
  • Community Forum
Epidemiology and Outcomes
You have accessRestricted Access

Chronic Kidney Disease and the Risk for Cardiovascular Disease, Renal Replacement, and Death in the United States Medicare Population, 1998 to 1999

Robert N. Foley, Anne M. Murray, Shuling Li, Charles A. Herzog, A. Marshall McBean, Paul W. Eggers and Allan J. Collins
JASN February 2005, 16 (2) 489-495; DOI: https://doi.org/10.1681/ASN.2004030203
Robert N. Foley
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anne M. Murray
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shuling Li
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charles A. Herzog
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. Marshall McBean
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul W. Eggers
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Allan J. Collins
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data Supps
  • Info & Metrics
  • View PDF
Loading

Abstract

Knowledge of the excess risk posed by specific cardiovascular syndromes could help in the development of strategies to reduce premature mortality among patients with chronic kidney disease (CKD). The rates of atherosclerotic vascular disease, congestive heart failure, renal replacement therapy, and death were compared in a 5% sample of the United States Medicare population in 1998 and 1999 (n = 1,091,201). Patients were divided into the following groups: 1, no diabetes, no CKD (79.7%); 2, diabetes, no CKD (16.5%); 3, CKD, no diabetes (2.2%); and 4, both CKD and diabetes (1.6%). During the 2 yr of follow-up, the rates (per 100 patient-years) in the four groups were as follows: atherosclerotic vascular disease, 14.1, 25.3, 35.7, and 49.1; congestive heart failure, 8.6, 18.5, 30.7, and 52.3; renal replacement therapy, 0.04, 0.2, 1.6, and 3.4; and death, 5.5, 8.1, 17.7, and 19.9, respectively (P < 0.0001). With use of Cox regression, the corresponding adjusted hazards ratios were as follows: atherosclerotic vascular disease, 1, 1.30, 1.16, and 1.41 (P < 0.0001); congestive heart failure, 1, 1.44, 1.28, and 1.79 (P < 0.0001); renal replacement therapy, 1, 2.52, 23.1, and 38.9 (P < 0.0001); and death, 1, 1.21, 1.38, and 1.56 (P < 0.0001). On a relative basis, patients with CKD were at a much greater risk for the least frequent study outcome, renal replacement therapy. On an absolute basis, however, the high death rates of patients with CKD may reflect accelerated rates of atherosclerotic vascular disease and congestive heart failure.

Chronic kidney disease (CKD) has become a common condition in the general population (1). Aging of the general population and an ongoing epidemic of diabetes are probable contributory factors (2). Some (3–5) but not all (6) recent studies have shown that patients with CKD have higher-than-expected death rates, even after adjustment for adverse prognostic factors that co-occur with CKD, such as older age, diabetes, and previous cardiovascular disease. Other studies suggest that CKD may act as a risk multiplier in patients who are hospitalized with symptomatic manifestations of cardiovascular disease, including patients with myocardial infarction and those with congestive heart failure (7–18). Renal replacement therapy is orders of magnitude less prevalent than CKD (19). These different strands of evidence suggest that identifying patients with CKD may have an importance beyond the mere identification of patients who are at risk for progressing to ESRD (20). The hypothesis that the higher death risk associated with CKD reflects higher rates of atherosclerotic vascular disease and congestive heart failure has clinical relevance. Kidney disease and cardiovascular disease both are approaching epidemic levels in the elderly. Both conditions seem to be lethally synergistic. Enumerating the degree by which kidney disease magnifies the risk for cardiovascular disease might inform screening and management strategies. For example, treating physicians might make greater efforts to identify and slow the progression of CKD and to treat modifiable risk factors such as obesity, lack of exercise, smoking, hyperlipidemia, and hypertension.

Materials and Methods

The objectives of this study were to compare patients with and without CKD on the basis of (1) cross-sectional associations with diabetes, age, demographic cardiovascular disease, and other comorbid conditions; (2) incidence of atherosclerotic vascular disease; (3) incidence of congestive heart failure; (4) incidence of renal replacement therapy; and (5) overall survival rates.

Design

Two phases were used. In the first phase, we identified Medicare patients who met the entry criteria (see the Patients section), which included survival from January 1, 1998, to December 31, 1999. Medicare claims during this 2-yr period were used to define patient characteristics, including age and the presence of CKD and/or diabetes on December 31, 1999. The second phase, which extended from January 1, 2000, to December 31, 2001, was used to define the major study outcomes.

Patients

We used the Medicare 5% Denominator File, a random sample based on health insurance claim numbers, to identify patients with the following characteristics: (1) age ≥65 yr on January 1, 1998; (2) residing in the 50 U.S. states, the District of Columbia, Puerto Rico, or the U.S. territories; (3) alive on December 31, 1999; (4) not receiving renal replacement therapy on December 31, 1999; and (5) continuously enrolled in both Medicare Part A and Part B from January 1, 1998, to December 31, 1999. Patients who were enrolled in a health maintenance organization and those with Medicare as secondary payer during this period were excluded.

Clinical conditions, with the exception of renal replacement therapy, were identified from Medicare claims according to a previously validated method for identifying diabetes (21). The International Classification of Diseases, Ninth Revision, Clinical Modification codes used to define each condition are shown in Appendix 1. Renal replacement therapy was identified by linking the Medicare 5% Denominator File to the United States Renal Data System database, which includes information on all patients who enter the renal replacement therapy program.

View this table:
  • View inline
  • View popup
Table 1.

Baseline patient characteristics on December 31, 1999a

View this table:
  • View inline
  • View popup
Table 2.

Incident event rates in 2000 to 2001a

View this table:
  • View inline
  • View popup
Table 3.

Adjusted hazards ratios (with 95% CI) for incident events in 2000 to 2001a

View this table:
  • View inline
  • View popup
Appendix 1.

ICD-9-CM codes used to identify clinical conditions

Statistical Analyses

The baseline associations of the four groups defined by the presence or absence of kidney disease and diabetes, as of December 31, 1999, were compared using χ2 analysis. In addition, the associations of CKD were examined using a logistic regression model in which diabetes was added to age, demographic variables, and clinical variables.

For each of the incident clinical outcomes, follow-up extended from January 1, 2000, until the earliest occurrence of the clinical event in question, renal replacement therapy, death, or December 31, 2001. We calculated event rates in each of the four groups defined by the presence or absence of kidney disease and diabetes. Population-attributable proportions for clinical events, according to the presence or absence of diabetes and/or CKD, were calculated as the product of (event rate in the exposed group − event rate in the nonexposed group) × (proportion of the population with the exposure of interest) ÷ (overall population rate event rate). The association between CKD and incident clinical outcomes was examined using Cox regression models that adjusted for diabetes, age, demographic variables, and clinical variables. All analyses were performed using SAS/STAT, version 8.2 (SAS Institute, Inc., Cary, NC).

Results

Table 1 shows the characteristics of the 1,091,201 study subjects as of December 31, 1999. The proportions with CKD (but not diabetes), with diabetes (but not CKD), and with both conditions were 2.2, 16.5, and 1.6%, respectively. Twenty-two percent of the study population had previous atherosclerotic vascular disease, and 13.8% had previous congestive heart failure. Using multivariate logistic regression, the following factors showed the largest cross-sectional associations (P < 0.0001) with CKD, based on adjusted odds ratios (OR): days hospitalized in the preceding 2 yr (OR, 4.62 for ≥20 d), anemia (OR, 2.13), hypertension (OR, 2.10), diabetes (OR, 2.04), congestive heart failure (OR, 1.96), male gender (OR, 1.56), liver disease (OR, 1.51), cancer (OR, 1.44), atherosclerotic vascular disease (OR, 1.42), and older age (OR, 1.10 for age ≥80 yr).

The defining cause of CKD was glomerulonephritis in 59.6%, hydronephrosis in 9.7%, diabetic nephropathy in 7.6%, hypertensive renal disease in 6.6%, kidney malignancy in 5.2%, renovascular disease in 4.9%, and other in 6.4%. Epoetin-α was used by 0.45% of the population studied (0.29% of non-CKD, nondiabetic subjects; 0.39% of non-CKD, diabetic subjects; 3.81% of CKD, nondiabetic subjects; and 4.33% of CKD, diabetic subjects). The corresponding figures for general urinalysis were 44.36, 41.86, 52.52, 61.60, and 44.36%; for urinalysis for microalbuminuria were 1.69, 0.25, 7.90, 0.85, and 10.20%; and for urinalysis for protein were 10.78, 9.35, 14.68, 21.17, and 10.78%.

Table 2 shows that the rates of the major study outcomes (i.e., atherosclerotic vascular disease, congestive heart failure, renal replacement therapy, and death) were 16.5, 10.8, 0.14, and 6.4 per 100 patient-years, respectively. Patients with CKD and diabetes had higher event rates than patients without these conditions (P < 0.0001). In nondiabetic patients, on an absolute basis, the largest discrepancy between those with and those without CKD was for congestive heart failure, with a difference in event rates of 22.1 per 100 patient-years, followed by atherosclerotic vascular disease (21.6 per 100 patient-years), death (12.2 per 100 patient-years), and renal replacement therapy (1.56 per 100 patient-years). Similar patterns were present among patients with diabetes, in whom the differences in event rates were 33.8 per 100 patient-years for congestive heart failure, 23.8 per 100 patient-years for atherosclerotic vascular disease, 11.8 per 100 patient-years for death, and 3.2 per 100 patient-years for renal replacement therapy. Figure 1 shows the corresponding population-attributable proportions for congestive heart failure, atherosclerotic vascular disease, renal replacement therapy, and death.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Population-attributable proportions (according to the presence of diabetes and/or chronic kidney disease [CKD]) for congestive heart failure, atherosclerotic vascular disease, renal replacement therapy, and death. Population-attributable proportions in the three exposure groups were calculated as (event rate in the exposed group − event rates in the group with neither diabetes nor CKD) × (proportion of the population with the exposure of interest) ÷ (overall population event rate). ASVD, atherosclerotic vascular disease; CHF, congestive heart failure, DM, diabetes mellitus; RRT, renal replacement therapy.

Table 3 shows adjusted hazards ratios for incident events in 2000 to 2001. CKD and diabetes were associated with each outcome. For atherosclerotic vascular disease and congestive failure, the following monotonic risk pattern was present: no CKD, no diabetes < CKD alone < diabetes alone < both CKD and diabetes. In contrast, for renal replacement therapy and death, the risk pattern was no CKD, no diabetes < diabetes alone < CKD alone < both CKD and diabetes. Adding epoetin-α, general urinalysis, urinalysis for microalbuminuria, and urinalysis for protein as covariates had negligible effects on the hazards ratios reported in Table 3.

Discussion

We found, on a relative basis, that the risk gradient associated with CKD was much greater for renal replacement therapy than it was for those associated with congestive heart failure and atherosclerotic vascular disease. However, atherosclerotic events and congestive heart failure were much more frequent in the study population than was renal replacement therapy. On an absolute basis, the high death rates among patients with CKD may reflect accelerated rates of atherosclerotic vascular disease and congestive heart failure.

It is not surprising that patients with CKD should be at a higher risk for ESRD than those without CKD. Also, the association between CKD and death that we observed has recently been observed by others (2–5). Recent studies in a general-population setting have suggested that mild to moderate CKD is associated with future cardiovascular events. The Cardiovascular Health Study was a prospective population-based study of subjects aged ≥65 yr, with an average follow-up of 7.3 yr. Renal insufficiency, defined as a serum creatinine value >1.5 mg/dl in men and >1.3 mg/dl in women, was present in 11.2% of participants. Subjects with renal insufficiency were more likely to develop cardiovascular disease, congestive heart failure, and symptomatic peripheral vascular disease, as well as to die; these associations were not eliminated by adjusting for traditional cardiovascular risk factors (3). Similarly, the Atherosclerosis Risk in Communities study, a prospective cohort study of subjects aged 45 to 64 yr, reported that a declining GFR was independently associated with the development of atherosclerotic cardiovascular disease (22). These findings are consistent with animal models suggesting that the metabolic internal milieu of CKD is both cardiotoxic and vasculotoxic (23,24).

Our study has several limitations. It was retrospective and used administrative claims to define the study population and the outcomes of interest. In particular, the assessment of CKD was not based on systematic estimates of kidney function but rather on qualitative clinical events. It is possible, therefore, that these “index” events account for some of the associations in this study. The proportion of the Medicare population with a diagnosis, by claims, of CKD was similar to the proportion of the general population with an estimated GFR of <60 ml/min per 1.73 m2; we suspect that most of the patients whom we studied fell into stage 3 (GFR, 30 to 59 ml/min per 1.73 m2), 4 (GFR, 15 to 29 ml/min per 1.73 m2), or 5 (kidney failure) of CKD (19). Similarly, characterization of comorbid conditions was heavily dependent on clinical events rather than systematic sampling. Validation of each of the variables studied here is clearly desirable. This is not an insignificant undertaking, however, as claims-based studies do not lend themselves easily to rigorous validation: In essence, a large-scale, national prospective study is required. Misclassification, whereby patients who, in reality, have CKD are considered as normal, and vice versa, would tend to bias toward the null. Thus, the CKD-associated risk gradients presented in this study may underestimate the true risk gradients associated with CKD. Finally, we examined a subset of patients, those who survived for 2 yr (January 1, 1998, to December 31, 1999); this was necessary to establish meaningful patient profiles. Similarly, this study included only Medicare enrollees, and its findings cannot be generalized to other populations.

We believe that the study has strengths. The sample size is large; therefore, the risk estimates have relatively tight confidence intervals. Comorbidity adjustment was extensive, and several events, based on clinical reality, were examined concurrently. We believe that this study has important implications. On an absolute basis, in patients with CKD, the risks for atherosclerotic vascular disease and congestive heart failure seem to be much greater than the risk for renal replacement therapy. Our findings suggest that screening strategies and therapeutic management should be tailored as much toward the prevention of cardiovascular disease as toward the prevention of ESRD.

Acknowledgments

The data reported here were supplied by the United States Renal Data System. This study was performed as a deliverable under Contract No. N01-DK-9-2343 (National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD).

We thank Shu-Cheng Chen and James Ebben for data management, Charena Lankford and Beth Forrest for regulatory assistance, and Dana D. Knopic and James Kaufmann for assistance with the manuscript.

Footnotes

  • Published online ahead of print. Publication date available at www.jasn.org.

  • © 2005 American Society of Nephrology

References

  1. ↵
    National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification and stratification. Am J Kidney Dis 39[Suppl 1] : S1 –S266, 2002
    OpenUrl
  2. ↵
    Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP: The continuing epidemics of obesity and diabetes in the United States. JAMA 286 : 1195 –1200, 2001
    OpenUrlCrossRefPubMed
  3. ↵
    Fried LF, Shlipak MG, Crump C, Bleyer AJ, Gottdiener JS, Kronmal RA, Kuller LH, Newman AB: Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals. J Am Coll Cardiol 41 : 1364 –1372, 2003
    OpenUrlCrossRefPubMed
  4. Henry RM, Kostense PJ, Bos G, Dekker JM, Nijpels G, Heine RJ, Bouter LM, Stehouwer CD: Mild renal insufficiency is associated with increased cardiovascular mortality: The Hoorn Study. Kidney Int 62 : 1402 –1407, 2002
    OpenUrlCrossRefPubMed
  5. ↵
    Muntner P, He J, Hamm L, Loria C, Whelton PK: Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol 13 : 745 –753, 2002
    OpenUrlAbstract/FREE Full Text
  6. ↵
    Garg AX, Clark WF, Haynes RB, House AA: Moderate renal insufficiency and the risk of cardiovascular mortality: Results from the NHANES I. Kidney Int 61 : 1486 –1494, 2002
    OpenUrlCrossRefPubMed
  7. ↵
    Langston RD, Presley R, Flanders WD, McClellan WM: Renal insufficiency and anemia are independent risk factors for death among patients with acute myocardial infarction. Kidney Int 64 : 1398 –1405, 2003
    OpenUrlCrossRefPubMed
  8. Santopinto JJ, Fox KA, Goldberg RJ, Budaj A, Pinero G, Avezum A, Gulba D, Esteban J, Gore JM, Johnson J, Gurfinkel EP: Creatinine clearance and adverse hospital outcomes in patients with acute coronary syndromes: Findings from the global registry of acute coronary events (GRACE). Heart 89 : 1003 –1008, 2003
    OpenUrlAbstract/FREE Full Text
  9. Wison S, Foo K, Cunningham J, Cooper J, Deaner A, Knight C, Ranjadayalan K, Timmis AD: Renal function and risk stratification in acute coronary syndromes. Am J Cardiol 91 : 1051 –1054, 2003
    OpenUrlCrossRefPubMed
  10. Freeman RV, Mehta RH, Al Badr W, Cooper JV, Kline-Rogers E, Eagle KA: Influence of concurrent renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the use of glycoprotein IIb/IIIa inhibitors. J Am Coll Cardiol 41 : 718 –724, 2003
    OpenUrlCrossRefPubMed
  11. Newby LK, Bhapkar MV, White HD, Topol EJ, Dougherty FC, Harrington RA, Smith MC, Asarch LF, Califf RM: Predictors of 90-day outcome in patients stabilized after acute coronary syndromes. Eur Heart J 24 : 172 –181, 2003
    OpenUrlCrossRefPubMed
  12. Walsh CR, O’Donnell CJ, Camargo CA Jr, Giugliano RP, Lloyd-Jones DM: Elevated serum creatinine is associated with 1-year mortality after acute myocardial infarction. Am Heart J 144 : 1003 –1011, 2002
    OpenUrlCrossRefPubMed
  13. Wright RS, Reeder GS, Herzog CA, Albright RC, Williams BA, Dvorak DL, Miller WL, Murphy JG, Kopecky SL, Jaffe AS: Acute myocardial infarction and renal dysfunction: A high-risk combination. Ann Intern Med 137 : 563 –570, 2002
    OpenUrlCrossRefPubMed
  14. Shlipak MG, Heidenreich PA, Noguchi H, Chertow GM, Browner WS, McClellan MB: Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients. Ann Intern Med 137 : 555 –562, 2002
    OpenUrlCrossRefPubMed
  15. Kalra PR, Collier T, Cowie MR, Fox KF, Wood DA, Poole-Wilson PA, Coats AJ, Sutton GC: Haemoglobin concentration and prognosis in new cases of heart failure. Lancet 362 : 211 –212, 2003
    OpenUrlCrossRefPubMed
  16. Bouvy ML, Heerdink ER, Leufkens HG, Hoes AW: Predicting mortality in patients with heart failure: A pragmatic approach. Heart 89 : 605 –609, 2003
    OpenUrlAbstract/FREE Full Text
  17. McClellan WM, Flanders WD, Langston RD, Jurkovitz C, Presley R: Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: a population-based study. J Am Soc Nephrol 13 : 1928 –1936, 2002
    OpenUrlAbstract/FREE Full Text
  18. ↵
    Kearney MT, Nolan J, Lee AJ, Brooksby PW, Prescott R, Shah AM, Zaman AG, Eckberg DL, Lindsay HS, Batin PD, Andrews R, Fox KA: A prognostic index to predict long-term mortality in patients with mild to moderate chronic heart failure stabilised on angiotensin converting enzyme inhibitors. Eur J Heart Fail 5 : 489 –497, 2003
    OpenUrlCrossRefPubMed
  19. ↵
    Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS: Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 41 : 1 –12, 2003
    OpenUrlCrossRefPubMed
  20. ↵
    Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G: National Kidney Foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Ann Intern Med 139 : 137 –147, 2003
    OpenUrlCrossRefPubMed
  21. ↵
    Hebert PL, Geiss LS, Tierney EF, Engelgau MM, Yawn BP, McBean AM: Identifying persons with diabetes using Medicare claims data. Am J Med Qual 14 : 270 –277, 1999
    OpenUrlCrossRefPubMed
  22. ↵
    Manjunath G, Tighiouart H, Ibrahim H, MacLeod B, Salem DN, Griffith JL, Coresh J, Levey AS, Sarnak MJ: Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol 41 : 47 –55, 2003
    OpenUrlPubMed
  23. ↵
    Tornig J, Amann K, Ritz E, Nichols C, Zeier M, Mall G: Arteriolar wall thickening, capillary rarefaction and interstitial fibrosis in the heart of rats with renal failure: The effects of ramipril, nifedipine, and moxonidine. J Am Soc Nephrol 7 : 667 –675, 1996
    OpenUrlAbstract
  24. ↵
    Amann K, Tyralla K, Gross ML, Eifert T, Adamczak M, Ritz E: Special characteristics of atherosclerosis in chronic renal failure. Clin Nephrol 60[Suppl 1] : S13 –S21, 2003
PreviousNext
Back to top

In this issue

Journal of the American Society of Nephrology: 16 (2)
Journal of the American Society of Nephrology
Vol. 16, Issue 2
1 Feb 2005
  • Table of Contents
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in JASN.
Enter multiple addresses on separate lines or separate them with commas.
Chronic Kidney Disease and the Risk for Cardiovascular Disease, Renal Replacement, and Death in the United States Medicare Population, 1998 to 1999
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Chronic Kidney Disease and the Risk for Cardiovascular Disease, Renal Replacement, and Death in the United States Medicare Population, 1998 to 1999
Robert N. Foley, Anne M. Murray, Shuling Li, Charles A. Herzog, A. Marshall McBean, Paul W. Eggers, Allan J. Collins
JASN Feb 2005, 16 (2) 489-495; DOI: 10.1681/ASN.2004030203

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Chronic Kidney Disease and the Risk for Cardiovascular Disease, Renal Replacement, and Death in the United States Medicare Population, 1998 to 1999
Robert N. Foley, Anne M. Murray, Shuling Li, Charles A. Herzog, A. Marshall McBean, Paul W. Eggers, Allan J. Collins
JASN Feb 2005, 16 (2) 489-495; DOI: 10.1681/ASN.2004030203
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data Supps
  • Info & Metrics
  • View PDF

More in this TOC Section

  • Survival among Patients with Kidney Failure in Jalisco, Mexico
  • A Population-Based, Prospective Study of Blood Pressure and Risk for End-Stage Renal Disease in China
  • Hepatitis C Virus and Death Risk in Hemodialysis Patients
Show more Epidemiology and Outcomes

Cited By...

  • Role of Platelets in Chronic Kidney Disease
  • Targeting Sedentary Behavior in CKD: A Pilot and Feasibility Randomized Controlled Trial
  • Impact of Chronic Kidney Disease on Outcomes of Myocardial Revascularization in Patients With Diabetes
  • Chronic kidney disease and cause-specific hospitalisation: a matched cohort study using primary and secondary care patient data
  • Add-On Antihypertensive Medications to Angiotensin-Aldosterone System Blockers in Diabetes: A Comparative Effectiveness Study
  • Uremic Solute-Aryl Hydrocarbon Receptor-Tissue Factor Axis Associates with Thrombosis after Vascular Injury in Humans
  • Non-uniform relationship between salt status and aldosterone activity in patients with chronic kidney disease
  • Epidemiology and Natural History of the Cardiorenal Syndromes in a Cohort with Echocardiography
  • Comparative effectiveness of allopurinol versus febuxostat for preventing incident renal disease in older adults: an analysis of Medicare claims data
  • Lipoprotein(a) and Risk of Myocardial Infarction and Death in Chronic Kidney Disease: Findings From the CRIC Study (Chronic Renal Insufficiency Cohort)
  • End-stage renal disease versus death in a Portuguese cohort of elderly patients: an approach using competing event analysis
  • Use of Electronic Health Data to Estimate Heart Failure Events in a Population-Based Cohort with CKD
  • Past Decline Versus Current eGFR and Subsequent Mortality Risk
  • Epidemiology and Mechanisms of Uremia-Related Cardiovascular Disease
  • Baseline FGF23 is Associated with Cardiovascular Outcome in Incident PD Patients
  • Interstate Variation in Receipt of Nephrologist Care in US Patients Approaching ESRD: Race, Age, and State Characteristics
  • High Parathyroid Hormone Level and Osteoporosis Predict Progression of Coronary Artery Calcification in Patients on Dialysis
  • Cause-Specific Deaths in Non-Dialysis-Dependent CKD
  • Impaired Myocardial Oxygenation Response to Stress in Patients With Chronic Kidney Disease
  • Implantable Cardioverter-Defibrillators in Patients with CKD: A Propensity-Matched Mortality Analysis
  • The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial
  • Vascular Calcification in Predialysis CKD: Common and Deadly
  • Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial
  • Recent Changes in Therapeutic Approaches and Association with Outcomes among Patients with Secondary Hyperparathyroidism on Chronic Hemodialysis: The DOPPS Study
  • Critical Blood Pressure Threshold Dependence of Hypertensive Injury and Repair in a Malignant Nephrosclerosis Model
  • Arterial Stiffness, Central Pressures, and Incident Hospitalized Heart Failure in the Chronic Renal Insufficiency Cohort Study
  • Association of Walking with Survival and RRT Among Patients with CKD Stages 3-5
  • Angiopoietin-2-Induced Arterial Stiffness in CKD
  • Diabetes and renal disease: who does what?
  • Cardiac Resynchronization Therapy in CKD: A Systematic Review
  • Interpreting Adverse Signals in Diabetes Drug Development Programs
  • Long-Term Nephrotoxicity in Adult Survivors of Childhood Cancer
  • Nonculprit Coronary Plaque Characteristics of Chronic Kidney Disease
  • Arterial disease in chronic kidney disease
  • A Transcriptional Blueprint for Human and Murine Diabetic Kidney Disease
  • Vascular Disease, ESRD, and Death: Interpreting Competing Risk Analyses
  • Risks of Death and End-Stage Renal Disease After Surgical Compared With Percutaneous Coronary Revascularization in Elderly Patients With Chronic Kidney Disease
  • Inflammation and the Paradox of Racial Differences in Dialysis Survival
  • Prognosis of CKD Patients Receiving Outpatient Nephrology Care in Italy
  • Dipstick Proteinuria as a Screening Strategy to Identify Rapid Renal Decline
  • Endogenous Erythropoietin and the Association with Inflammation and Mortality in Diabetic Chronic Kidney Disease
  • Chronic kidney disease in patients with diabetes mellitus type 2 or hypertension in general practice
  • Impact of Age and Overt Proteinuria on Outcomes of Stage 3 to 5 Chronic Kidney Disease in a Referred Cohort
  • Republished paper: Arterial stiffness in chronic kidney disease: causes and consequences
  • Rate of ESRD Exceeds Mortality among African Americans with Hypertensive Nephrosclerosis
  • Higher Incidence of ESRD than Mortality in the AASK Study
  • Chronic Kidney Disease as a Potent Risk Modifier for CAD in Diabetics
  • Arterial stiffness in chronic kidney disease: causes and consequences
  • Geriatric Nephrology: Responding to a Growing Challenge
  • ENDOTOXEMIA IS ASSOCIATED WITH BETTER CLINICAL OUTCOME IN INCIDENT CHINESE PERITONEAL DIALYSIS PATIENTS: A PROSPECTIVE COHORT STUDY
  • Physical Activity and Mortality in Chronic Kidney Disease (NHANES III)
  • Longitudinal Relationships among Coronary Artery Calcification, Serum Phosphorus, and Kidney Function
  • Prediction, Progression, and Outcomes of Chronic Kidney Disease in Older Adults
  • Cystatin C Levels in U.S. Adults, 1988-1994 Versus 1999-2002: NHANES
  • Erythropoietin Therapy and Left Ventricular Mass Index in CKD and ESRD Patients: A Meta-Analysis
  • Anemia: The Point of Convergence or Divergence for Kidney Disease and Heart Failure?
  • Perspectives on eGFR reporting from the Interface between Primary and Secondary Care
  • The Costs and Benefits of Automatic Estimated Glomerular Filtration Rate Reporting
  • Chronic Kidney Disease in the United States: A Public Policy Imperative
  • Associations of Kidney Function with Cardiovascular Medication Use after Myocardial Infarction
  • Aortic distensibility and arterial-ventricular coupling in early chronic kidney disease: a pattern resembling heart failure with preserved ejection fraction
  • Combined Effect of Chronic Kidney Disease and Peripheral Arterial Disease on All-Cause Mortality in a High-Risk Population
  • Managing Dyslipidemia in Chronic Kidney Disease
  • Relation of Low Glomerular Filtration Rate to Metabolic Disorders in Individuals without Diabetes and with Normoalbuminuria
  • Endotoxemia is Related to Systemic Inflammation and Atherosclerosis in Peritoneal Dialysis Patients
  • Oxidative Stress and Inflammation Are Associated with Adiposity in Moderate to Severe CKD
  • Vascular Stiffness: Its Measurement and Significance for Epidemiologic and Outcome Studies
  • Age Affects Outcomes in Chronic Kidney Disease
  • Are Patients Who Have Metabolic Syndrome without Diabetes at Risk for Developing Chronic Kidney Disease? Evidence Based on Data from a Large Cohort Screening Population
  • Diabetes Management Issues for Patients With Chronic Kidney Disease
  • Carotid Intima Media Thickness Predicts Cardiovascular Diseases in Chinese Predialysis Patients with Chronic Kidney Disease
  • Pulse Wave Velocity Is Inversely Related to Vertebral Bone Density in Hemodialysis Patients
  • Longitudinal Study of Racial and Ethnic Differences in Developing End-Stage Renal Disease among Aged Medicare Beneficiaries
  • Anemia and Cardiovascular Risk: The Lesson of the CREATE Trial
  • Google Scholar

Similar Articles

Related Articles

  • This Month’s Highlights
  • PubMed
  • Google Scholar

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Annual Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Author Resources
  • Editorial Fellowship Program
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • JASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About JASN
  • JASN Email Alerts
  • JASN Key Impact Information
  • JASN Podcasts
  • JASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe to ASN Journals

© 2022 American Society of Nephrology

Print ISSN - 1046-6673 Online ISSN - 1533-3450

Powered by HighWire